Original scientific paper

Congental myasthenic syndromes - diagnostics and treatment

N. Barišić
J. Mueller
I. Leman
A. Šribar
A. Abicht
H. Lochmueller

Abstract

Congenital myasthenic syndromes (CMS) are genetically determined disorders affecting safety margins of neural transmission at presynaptic, postsynaptic and synaptic level. Diagnosis of CMS is made based on clinical symptoms including fatigable muscle weakness since infancy or childhood, decremental EMG response and negative antibodies to acetylcholine receptors (AchR) and muscle specific tyrosine kinase (MuSK). In some CMS the onset is delayed, weakness and EMG abnormalities appear intermittently in restricted distribution. Molecular genetic analysis has an important role in diagnosis of CMS. Presynaptic CMS are associated with recessive CHAT (cholinacyltransferase) gene mutations. The synaptic disorder is caused by mutation of the collagenic tail subunit of the AchE gene. However most CMS are postsynaptic, mostly caused by CHRNE gene mutations of AchR ε-subunit. In general, nonsense or frame shifting mutations cause CMS by decreased or absent protein expression and are inherited in autosomal recessive traits. Rapsyn gene (RAPSN) mutations cause primary endplate AchR deficiency. AchE inhibitors are the drugs of first choice in the treatment of CMS.
We present children with presynaptic and with postsynaptic defects manifesting remarkable clinical heterogeneity.

Keywords

Descriptors: MYASTHENIC SYNDROMES; CONGENITAL – diagnosis; drug therapy

Hrčak ID:

18025

URI

https://hrcak.srce.hr/18025

Publication date:

23.11.2007.

Article data in other languages: croatian

Visits: 10.301 *